Cracking Down on Counterfeiting - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cracking Down on Counterfeiting


Pharmaceutical Technology


The information a drug pedigree should contain is codified in 21 CFR 203.50, but FDA does not have the statutory authority to implement a uniform requirement that would supersede state requirements. And, it cannot mandate a universal requirement that includes all wholesalers. This means stakeholders may have to meet federal as well as multiple state pedigree requirements, and there may be pedigree gaps unless Congress passes legislation in these areas.

Data management. E-pedigree implementation also depends on the data management that enables information sharing among all members of the supply chain from a central database or a distributed system where information is stored on various company servers. Data security is imperative. The Task Force expressed no preference between a centralized or distributed data storage system and noted that a hybrid environment may be the optimum solution. The report goes on to say, "We do believe that it is essential that every entity in a drug product's chain of custody have access to the product's pedigree data all the way back to the manufacturer, in order to verify and authenticate the pedigree. It is also important for FDA to have access to the information in matters of suspect illegal activity" (1).

Some assistance with data management may be generated by a collaborative effort between the HDMA Foundation, the research arm of the Healthcare Distribution Management Association (Arlington, VA, http://www.healthcaredistribution.org), and the Rutgers Center for Supply Chain Management (New Brunswick, NJ, http://www.scm.rutgers.edu/index.htm).

Privacy concerns. The Task Force stated that privacy issues must be addressed and noted that "consumer education is necessary" regarding the presence and purpose of RFID. Toward that end, it recommends the agency support the industry's education efforts and "work with manufacturers and other stakeholders in their efforts to develop appropriate messages, symbols, or statements for labeling of drug products and packaging that contains an RFID tag" (1).

Another privacy issue to be worked out is whether to deactivate or remove an RFID tag and at what point in the supply chain this should be done. Tag deactivation may be addressed in the standards-making process or may have to wait until the e-pedigree process is more mature. "We believe that this issue warrants further discussion among stakeholders, technology experts, and consumers, about the viable options," states the report (1).

The stay on pedigree requirements will expire in a few months, so members of the pharmaceutical supply chain must accelerate their pedigree data collection efforts now. The report concludes, "With the implementation of the PDMA [pedigree] regulations in December 2006, we expect that supply chain stakeholders will move quickly to adopt electronic track and trace technology, implementing RFID in a phased-in approach . . . companies should continue to tag drug products, build infrastructure across the supply chain for using an e-pedigree, and remain vigilant to their responsibility to provide a safe and effective drug product to the patient" (1).

References

1. US Food and Drug Administration, FDA Counterfeit Drug Task Force Report: 2006 Update (FDA, Rockville, MD, June 2006), http:// http://www.fda.gov/oc/initiatives/counterfeit/report6_06.html, accessed July 11, 2006.

2. FDA, Draft Compliance Policy Guide 160.900, Prescription Drug Marketing Act: Pedigree Requirements under 21 CFR Part 203 (FDA, Rockville, MD, June 2006), http:// http://www.fda.gov/oc/initiatives/counterfeit/cpg.html, accessed July 11, 2006.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here